Salarius Pharmaceuticals Inc (SLRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SLRX POWR Grades
- Sentiment is the dimension where SLRX ranks best; there it ranks ahead of 74.87% of US stocks.
- SLRX's strongest trending metric is Growth; it's been moving down over the last 38 weeks.
- SLRX's current lowest rank is in the Momentum metric (where it is better than 4.46% of US stocks).
SLRX Stock Summary
- For SLRX, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
- With a year-over-year growth in debt of -100%, Salarius Pharmaceuticals Inc's debt growth rate surpasses only 0% of about US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SLRX comes in at -79.09% -- higher than that of only 3.35% of stocks in our set.
- Stocks that are quantitatively similar to SLRX, based on their financial statements, market capitalization, and price volatility, are MNDO, APVO, ONTX, SINT, and RDCM.
- SLRX's SEC filings can be seen here. And to visit Salarius Pharmaceuticals Inc's official web site, go to www.salariuspharma.com.
SLRX Valuation Summary
- SLRX's price/sales ratio is 9.9; this is 12.78% lower than that of the median Healthcare stock.
- SLRX's price/sales ratio has moved NA NA over the prior 80 months.
- SLRX's price/sales ratio has moved NA NA over the prior 80 months.
Below are key valuation metrics over time for SLRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SLRX | 2021-08-31 | 9.9 | 1.0 | -5.3 | -1.6 |
| SLRX | 2021-08-30 | 9.5 | 1.0 | -5.1 | -1.4 |
| SLRX | 2021-08-27 | 9.5 | 1.0 | -5.1 | -1.4 |
| SLRX | 2021-08-26 | 9.6 | 1.0 | -5.1 | -1.4 |
| SLRX | 2021-08-25 | 9.5 | 1.0 | -5.1 | -1.4 |
| SLRX | 2021-08-24 | 9.0 | 0.9 | -4.8 | -1.1 |
SLRX Growth Metrics
- The 2 year price growth rate now stands at -99.23%.
- The 4 year price growth rate now stands at -99.67%.
- Its year over year cash and equivalents growth rate is now at 279.52%.
The table below shows SLRX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-06-30 | 4.697377 | -10.02412 | -8.806852 |
| 2021-03-31 | 5.3693 | -9.326119 | -7.516741 |
| 2020-12-31 | 5.233301 | -10.31136 | -7.748661 |
| 2020-09-30 | 4.793072 | -11.57444 | -7.467527 |
| 2020-06-30 | 4.289782 | -14.3229 | -8.378616 |
| 2020-03-31 | 3.211177 | -12.62938 | -7.979135 |
SLRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SLRX has a Quality Grade of D, ranking ahead of 5.84% of graded US stocks.
- SLRX's asset turnover comes in at 0.129 -- ranking 240th of 681 Pharmaceutical Products stocks.
- Service Unavailable
The table below shows SLRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.129 | 1.000 | -2.587 |
| 2021-03-31 | 0.183 | 1.000 | -2.888 |
| 2020-12-31 | 0.242 | 1.000 | -4.816 |
| 2020-09-30 | 0.254 | 1.000 | -15.428 |
| 2020-06-30 | 0.256 | 1.000 | 9.857 |
| 2020-03-31 | 0.231 | 0.989 | 6.965 |
SLRX Price Target
For more insight on analysts targets of SLRX, see our SLRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.43 | Average Broker Recommendation | 1.33 (Strong Buy) |
SLRX Stock Price Chart Interactive Chart >
SLRX Price/Volume Stats
| Current price | $0.87 | 52-week high | $3.50 |
| Prev. close | $0.90 | 52-week low | $0.63 |
| Day low | $0.87 | Volume | 576,800 |
| Day high | $0.93 | Avg. volume | 1,856,482 |
| 50-day MA | $0.99 | Dividend yield | N/A |
| 200-day MA | $1.24 | Market Cap | 39.15M |
Salarius Pharmaceuticals Inc (SLRX) Company Bio
Salarius Pharmaceuticals Inc is a clinical-stage oncology company. The Company specializes in targeting the epigenetic causes of cancers and developing treatments for patients. Salarius Pharmaceuticals serves patients and customers in the State of Texas.
Latest SLRX News From Around the Web
Below are the latest news stories about Salarius Pharmaceuticals Inc that investors may wish to consider to help them evaluate SLRX as an investment opportunity.
Salarius Pharmaceuticals and Nationwide Children’s Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsHOUSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, and Nationwide Children’s Hospital announced today research findings from their presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. The conference begins today, October 7, 2021, and runs through |
Salarius Pharmaceuticals to Present at the 2021 BioFuture ConferenceHOUSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief Executive Officer, will present virtually at the 2021 BioFuture Conference. The event will be held in New York City on October 5-6, 2021, at Cure, Deerfield Management Company’s vertical healthcare-dedica |
Salarius Pharmaceuticals and Nationwide Children’s Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsHOUSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, and Nationwide Children’s Hospital disclosed today that an abstract has been accepted by the American Association for Cancer Research (AACR) for poster presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Ther |
Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of TexasHOUSTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced the receipt of a $2.7 million payment under its existing contract with the Cancer Prevention and Research Institute of Texas (CPRIT). The payment is part of a non-dilutive grant that was originally awarded in 2016 to support Sal |
Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap ConferenceHOUSTON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief Executive Officer, will present virtually at the Benzinga Healthcare Small Cap Conference taking place September 29-30, 2021. The live virtual presentation can be accessed via the conference’s virtual pl |
SLRX Price Returns
| 1-mo | -17.14% |
| 3-mo | 0.75% |
| 6-mo | -28.69% |
| 1-year | 5.45% |
| 3-year | -93.95% |
| 5-year | -99.44% |
| YTD | -4.40% |
| 2020 | -75.93% |
| 2019 | -54.18% |
| 2018 | -90.54% |
| 2017 | -33.90% |
| 2016 | -57.59% |
Loading social stream, please wait...